Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Simulations Plus stock | $57.82

Own Simulations Plus stock in just a few minutes.

Fact checked

Simulations Plus, Inc is a health information services business based in the US. Simulations Plus shares (SLP) are listed on the NASDAQ and all prices are listed in US Dollars. Simulations Plus employs 129 staff and has a trailing 12-month revenue of around USD$41.6 million.

How to buy shares in Simulations Plus

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Simulations Plus. Find the stock by name or ticker symbol: SLP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Simulations Plus reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$57.82, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Simulations Plus, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Simulations Plus. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Simulations Plus share price

Use our graph to track the performance of SLP stocks over time.

Simulations Plus shares at a glance

Information last updated 2020-11-27.
Latest market closeUSD$57.82
52-week rangeUSD$25.9173 - USD$77.8233
50-day moving average USD$67.952
200-day moving average USD$61.2904
Wall St. target priceUSD$82.75
PE ratio 112
Dividend yield USD$0.24 (0.43%)
Earnings per share (TTM) USD$0.5

Buy Simulations Plus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Simulations Plus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Simulations Plus price performance over time

Historical closes compared with the close of $57.82 from 2020-12-09

1 week (2021-01-08) -29.76%
1 month (2020-12-15) -3.67%
3 months (2020-10-15) -19.58%
6 months (2020-07-15) -7.31%
1 year (2020-01-15) 74.42%
2 years (2019-01-15) 190.26%
3 years (2018-01-12) 254.72%
5 years (2016-01-15) 448.06%

Is Simulations Plus under- or over-valued?

Valuing Simulations Plus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Simulations Plus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Simulations Plus's P/E ratio

Simulations Plus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 112x. In other words, Simulations Plus shares trade at around 112x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Simulations Plus's PEG ratio

Simulations Plus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.5392. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Simulations Plus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Simulations Plus's EBITDA

Simulations Plus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$14.4 million.

The EBITDA is a measure of a Simulations Plus's overall financial performance and is widely used to measure a its profitability.

Simulations Plus financials

Revenue TTM USD$41.6 million
Operating margin TTM 31.31%
Gross profit TTM USD$30.9 million
Return on assets TTM 7.62%
Return on equity TTM 9.64%
Profit margin 22.44%
Book value $7.832
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Simulations Plus shares

There are currently 1.4 million Simulations Plus shares held short by investors – that's known as Simulations Plus's "short interest". This figure is 2.3% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Simulations Plus shares can be evaluated.

Simulations Plus's "short interest ratio" (SIR)

Simulations Plus's "short interest ratio" (SIR) is the quantity of Simulations Plus shares currently shorted divided by the average quantity of Simulations Plus shares traded daily (recently around 182953.2885906). Simulations Plus's SIR currently stands at 7.45. In other words for every 100,000 Simulations Plus shares traded daily on the market, roughly 7450 shares are currently held short.

However Simulations Plus's short interest can also be evaluated against the total number of Simulations Plus shares, or, against the total number of tradable Simulations Plus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Simulations Plus's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Simulations Plus shares in existence, roughly 60 shares are currently held short) or 0.079% of the tradable shares (for every 100,000 tradable Simulations Plus shares, roughly 79 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Simulations Plus.

Find out more about how you can short Simulations Plus stock.

Simulations Plus share dividends


Dividend payout ratio: 48% of net profits

Recently Simulations Plus has paid out, on average, around 48% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.43% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Simulations Plus shareholders could enjoy a 0.43% return on their shares, in the form of dividend payments. In Simulations Plus's case, that would currently equate to about $0.24 per share.

While Simulations Plus's payout ratio might seem fairly standard, it's worth remembering that Simulations Plus may be investing much of the rest of its net profits in future growth.

Simulations Plus's most recent dividend payout was on 2 November 2020. The latest dividend was paid out to all shareholders who bought their shares by 23 October 2020 (the "ex-dividend date").

Have Simulations Plus's shares ever split?

Simulations Plus's shares were split on a 2:1 basis on 2 October 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Simulations Plus shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Simulations Plus shares which in turn could have impacted Simulations Plus's share price.

Simulations Plus share price volatility

Over the last 12 months, Simulations Plus's shares have ranged in value from as little as $25.9173 up to $77.8233. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Simulations Plus's is 0.0124. This would suggest that Simulations Plus's shares are less volatile than average (for this exchange).

Simulations Plus overview

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site